Articles from Xcellerant Ventures

Xcellerant Ventures (XVC) is proud to announce its investment in Mindset Medical (Mindset), a Phoenix-based digital health company pioneering software-only, contactless vital sign monitoring. This investment marks the latest addition to Xcellerant VC Fund 1, underscoring the fund's commitment to backing transformative healthcare technologies. John Shufeldt, Managing Partner at XVC, will join the board.

Xcellerant Ventures (XVC) is proud to announce a strategic partnership with AZ Venture Capital Inc. (AVC), bringing $7 million in new funding to Arizona-based health technology startups. The $7 million, total, that is available for Arizona startups was made possible by a $5 million investment by AVC into XVC’s Fund. According to Douglas Sylvester, a general partner in XVC, “The $5 million from AZ Venture Capital spurred our investors to add $2 million to our Fund. This additional funding strengthens the state’s growing position as a hub for healthcare innovation, empowering entrepreneurs to develop transformative solutions that improve patient care, accessibility, and affordability.”

Xcellerant Ventures is proud to announce that it will lead DeepLook Medical’s Series A funding round. DeepLook Medical, a healthtech company specializing in visual enhancement technology for advanced medical imaging, marks the 11th investment in Xcellerant VC Fund 1. Michael Shufeldt, MBA, Principal at Xcellerant Ventures, will join the board.

Xcellerant Ventures is proud to announce its investment in CRISPR QC, the San Diego-based biotechnology company that has developed the world’s first platform to precisely analyze the quality of the CRISPR/CAS9 gene editing system. By providing a way to standardize measurements for efficiency and accuracy, CRISPR QC enables pharmaceutical and agriculture companies to quickly screen for the best therapeutics to develop into next generation personalized medicines.

Xcellerant Ventures welcomes Lenoss Medical into our Venture Fund I portfolio. Lenoss Medical is disrupting the treatment of spinal fractures with their OsteoPearl VBA System. This minimally invasive and cement-free technology delivers a fully biologic solution to stabilize spinal fractures and utilizes the natural healing properties of healthy bone. “There is no longer a need to utilize cement to treat osteoporotic spinal fractures. This is a common-sense solution that eliminates a major risk associated with vertebral compression fracture surgeries and promotes healing at the same time. Their CEO Dom Messerli is a visionary leader, and we are thrilled to be a major investor in this round of financing,” says Xcellerant Ventures General Partner John Shufeldt.

Xcellerant Ventures (XVC) welcomes the Flinn Foundation as a limited partner in its Xcellerant Venture Capital Fund I. Xcellerant Ventures is a venture capital firm investing in early and seed stage startups within the HealthTech and MedTech sectors. Xcellerant seeks to invest in dynamic founding teams with strong intellectual property portfolios that XVC believes will transform medical practice and dramatically improve healthcare.